Saturday, December 17, 2016

Avastin ( Bevacizumab) Approval Expanded for Platinum Sensitive Ovarian Cancer

Earlier this month the FDA approved the expanded use of Avastin (bevacizumab) for platinum sensitive ovarian cancer (OC) . Being platinum sensitive means that a women has a recurrence 6 months or more from her last treatment.

Avastin may be used for:
"Recurrent epithelial ovarian , fallopian tube or primary peritoneal cancer that is
  • platinum-resistant in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan
  • platinum-sensitive in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed byAvastin as a single agent (1.6) "
The complete label of use for Avastin / bevacizumab may be found here.

This approval is based on two phase III studies. One study, GOG-213, showed a 5 month longer overall survival for women with platinum sensitive OC when treated with  bevacizumab and chemotherapy versus chemotherapy alone. The other study, OCEANS, showed a median progression free survival of  4 months for those receiving Avastin and chemotherapy versus those receiving placebo and chemotherapy.

Avastin had previously been approved in 2014 for women with platinum resistant ovarian cancer, fallopian tube and primary peritoneal in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan chemotherapy.


Dee
Every Day is a Blessing! Happy to see more options for women with platinum sensitive OC. 



Sources
Roche:
http://www.roche.com/media/store/releases/med-cor-2016-12-07.htm

Cure Today:
http://www.curetoday.com/articles/avastin-gets-expanded-fda-approval-for-platinumsensitive-ovarian-cancer 

Genentech:
https://www.gene.com/media/press-releases/14647/2016-12-06/fda-approves-genentechs-avastin-bevacizu

No comments: